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Original StudyAdded Value of Contrast-Enhanced T1-Weighted
and Diffusion-Weighted Sequences for
Characterization of Incidental Findings on Whole
Body Magnetic Resonance Imaging in Plasma-Cell
Disorders
Olwen Westerland,1,3 Nishanth Sivarasan,1 Sarah Natas,1 Hema Verma,1
Sarah McElroy,1 Jessica M. Winﬁeld,1 Radhouene Neji,3,4 Inas El-Najjar,2
Majid Kazmi,2 Matthew Streetly,2 Vicky Goh1,3
Abstract
Incidental ﬁndings on whole body magnetic resonance imaging (WBMRI) in myeloma may necessitate addi-
tional investigations. Incidence, characterization, and signiﬁcance of incidental ﬁndings at WBMRI in 100
patients with plasma-cell disorders were calculated. A total of 348 ﬁndings were detected in 97 of 100 patients;
38 of 348 ﬁndings were indeterminate, and no additional cancers were detected. Incidental ﬁndings are
common, but the majority can be characterized at WBMRI and are not signiﬁcant.
Background: Whole body magnetic resonance imaging (WBMRI) is currently recommended by guidelines for the
assessment of myeloma. This will inevitably result in incidental ﬁndings. We aimed to assess the frequency of
extraskeletal incidental ﬁndings and the added value of contrast-enhanced (CE) T1-weighted (T1-W) and diffusion-
weighted (DWI) sequences for their characterization in a single WBMRI examination. Patients and Methods: We
performed 1.5 T WBMRI in 100 patients (53 female; median age, 65 years) with plasma-cell disorders from January
2014 to July 2017. T2-weighted sequences were reviewed initially for incidental ﬁndings, followed by sequential review
of T1-W, CE T1-W, and DWI sequences for lesion characterization. Descriptive statistics were undertaken. Results: A
total of 348 incidental ﬁndings were detected in 97 (97%) of 100 patients; only 38 (10.9%) of 348 ﬁndings were
indeterminate. T1-W sequences increased diagnostic conﬁdence in the characterization of 12 (31.6%) of 38; CE T1-W
sequences in the characterization of 16 (50%) of 32; and DWI increased diagnostic conﬁdence in 21 (55.3%) of 38
compared to the T2-weighted sequence alone. Conclusion: Incidental ﬁndings are common, but the majority are of no
clinical consequence. No additional cancers were noted in our series. DWI and CE T1-W sequences increased
diagnostic conﬁdence in 50% of indeterminate ﬁndings and may reduce the need for further investigation.
Clinical Lymphoma, Myeloma & Leukemia, Vol. -, No. -, --- ª 2018 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction myeloma.1 The International Myeloma Working Group guidelines
The revised International Myeloma Working Group guidelines
now state that the presence of more than one focal magnetic
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https://doi.org/10.1016/j.clml.2018.08.006also speciﬁcally advocate whole body magnetic resonance imaging
(WBMRI) in the initial assessment of smoldering myeloma because
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Incidental Findings on WBMRIexcellent tissue contrast and high spatial resolution, WBMRI pro-
vides a comprehensive approach to skeletal and extraskeletal
assessment. WBMRI will deﬁne disease burden through the number
and location of skeletal lesions, the pattern of disease, and the
presence of extraosseous sites, as well as clinically signiﬁcant com-
plications such as fractures and cord/cauda equina compression.
Thus clinical practice guidelines are changing. Whole body MRI
(WBMRI) is now recommended in the United Kingdom by the
National Institute for Health and Care Excellence as the ﬁrst-line
imaging test for suspected and newly diagnosed myeloma.2 The
2017 British Society of Haematology guidelines also recommend
WBMRI as the ﬁrst-line imaging test in asymptomatic patients with
10% to 60% plasma cells on trephine biopsy or bone marrow
aspirate, or an M protein > 30 g/L.3
Incidental ﬁndings are inevitable with whole body studies and
may require further investigations, adding to patient anxiety. Up to
58% of incidental ﬁndings may be indeterminate in nature.4 We
hypothesized that a comprehensive WBMRI protocol including T2-
weighted (T2-W), T1-weighted (T1-W), contrast-enhanced (CE)
T1-W, and diffusion-weighted (DWI) sequences will improve the
characterization of incidental ﬁndings and potentially reduce the
need for further investigations. We thus aimed to determine (1) the
frequency of incidental ﬁndings in patients undergoing WBMRI for
plasma-cell disorders in our institution, (2) their clinical signiﬁ-
cance, and (3) the added value of T1-W, CE T1-W, and DWI
sequences in the characterization of indeterminate ﬁndings.
Patients and Methods
Patients
Institutional review board approval was obtained; the need for
informed consent was waived for this retrospective audit of practice.
One hundred patients with suspected or proven plasma-cellTable 1 Whole Body Magnetic Resonance Imaging Protocol
Image Contrast T1-W
DWI (b-Va
and 900 s
Sequence Dixon 3-D FLASH DW-E
Imaging plane Axial Axia
No. of slices per imaging station 40 4
Acquired slice thickness (mm) 10
Reconstructed slice thickness (mm) 5
Slice gap (mm) 0
FOV (mm) 500 50
Acquired voxels (mm  mm) 2  1.6 3.9 
Reconstructed matrix 640 25
Reconstructed voxels (mm  mm) 0.8  0.8 2.0 
Phase-encoding direction AP AP
TR (ms) 6.62 627
TE (ms) TE1 ¼ 2.39, TE 2 ¼ 4.77 6
Flip angle (degrees) 10 9
No. of signal averages 1 2 (b50), 5
Fat suppression NA STIR
Acquisition time (per station) 10 sec 3 min 2
Abbreviations: AP ¼ anterior to posterior; DW-EPI ¼ diffusion-weighted echo planar imaging; FH ¼
recovery; TE ¼ echo time; TR ¼ repetition time; W ¼ weighted.
nical Lymphoma, Myeloma & Leukemia Month 2018disorders underwent WBMRI between January 2014 and July
2017. There were 53 female and 47 male patients with a median age
of 65 years (range, 38-90 years) who had the following conﬁrmed
diagnoses: myeloma ¼ 63, smoldering myeloma ¼ 11, monoclonal
gammopathy of unknown signiﬁcance ¼ 12, plasmacytoma ¼ 6,
and other diagnoses ¼ 8 (suspected myeloma ¼ 3, amyloidosis ¼ 3,
lymphoma ¼ 1, demyelinating neuropathy ¼ 1).
Imaging and Image Analysis
WBMRI consisting of T2-W, T1-W, DWI (b-value ¼ 50 and
900 s/mm2), and CE T1-W sequences from the skull vertex to
knees was performed at 1.5 T (Magnetom Aera; Siemens Health-
care, Erlangen, Germany) (Table 1). WBMRI study duration was
approximately 45 minutes. Intravenous contrast administration (20
mL gadoterate meglumine) was only possible in 82 (82%) of 100
patients because of renal impairment.
T2-W sequences were reviewed initially for incidental ﬁndings,
followed by a dedicated review of T1-W, CE T1-W, and DWI
sequences including apparent diffusion coefﬁcient maps by a staff
radiologist with 7 years of MRI experience. Findings, their site, and
likely diagnoses were noted. On the basis of review of T2-W se-
quences, these ﬁndings were also categorized as follows: I, common
in asymptomatic subjects/not clinically signiﬁcant; IIA, benign and
potentially clinically signiﬁcant; IIB, indeterminate and potentially
malignant; or III, requiring urgent clinical input.
For indeterminate ﬁndings that could not be characterized
initially on the T2-W sequence, the likelihood of malignancy was
recorded for each additional sequence (T1-W, CE T1-W, and
DWI) as follows: I, benign, II, probably benign, III, indeterminate,
IV, probably malignant, or V, malignant.
The diagnostic conﬁdence for likely diagnosis was also scored for
T1-W, CE T1-W, and DWI sequences independent of each otherlues 50
/mm2) T2-W T1-W (Pre- and Postcontrast)
PI HASTE Dixon 3-D FLASH
l Axial Coronal
0 40 128
5 5 10
5 5 2.0
0 0 0
0 500 500
3.9 2.0  2.0 1.9  0.17
6 512 288
2.0 1.0  1.0 1.7  1.7
AP FH
0 400 6.76
7 92 TE1 ¼ 2.39, TE2 ¼ 4.77
0 90; refocusing angle 180 10
(b900) 1 1
None NA
2 sec 16 sec 20 sec
foot to head; FLASH ¼ fast low-angle shot; FOV ¼ ﬁeld of view; STIR ¼ short TI inversion
Table 2 Summary of Incidental Findings by Body Region
Incidental Finding N % Category
Intracranial
Sinusitis 34 9.8 I
Small vessel disease 16 4.6 IIA
Infarct 3 0.9 IIA
Vestibular schwannoma 1 0.3 IIB
Neck
Thyroid lesion/cyst 6 1.7 I
Cervical/supraclavicular fossa
lymph node
2 0.6 IIB
Parotid Warthin tumor 1 0.3 IIB
Chest
Pleural effusion 7 2.0 IIA
Pulmonary lesion 3 0.9 IIB
Cardiomegaly 2 0.6 IIA
Chest wall lipoma 2 0.6 I
Abdomen
Hepatic/renal/splenic cysts 80 23.0 I
Colonic diverticulosis 18 5.2 IIA
Cholelithiasis 9 2.6 IIA
Indeterminate liver/splenic
lesion
7 2.0 IIB
Adrenal lesion/thickening 5 1.4 IIB
Pancreatic cystic lesion 5 1.4 IIB
Pelvis
Uterine ﬁbroid 18 5.2 IIA
Prostate lesion 5 1.4 IIB
Adnexal lesion 5 1.4 IIB
Adenomyosis 2 0.6 IIA
Inguinal hernia 2 0.6 IIA
Proximal Lower Limb
Baker cyst 2 0.6 IIA
Knee effusion 1 0.3 IIA
Olwen Westerland et alin order to ascertain the added value of each additional sequence for
lesion characterization compared to the initial T2-W sequence.
Reference Standard
Electronic patient records were reviewed in order to conﬁrm
whether the incidental ﬁndings detected at WBMRI resulted in
further investigations, including further imaging tests and biopsy,
and the ﬁnal diagnosis. Where no further information was available,
clinical consensus regarding the clinical signiﬁcance and whether
further management would have been undertaken was agreed by 2
hematologists. Clinical signiﬁcance was graded as follows: unknown,
low signiﬁcance, moderate signiﬁcance (meriting further routine
investigation), and high signiﬁcance (meriting urgent investigation).
Statistical Analysis
Descriptive statistics were undertaken by SPSS 24 software (IBM,
Armonk, NY).
Results
A total of 348 incidental ﬁndings were detected on the T2-W
sequences in 97 (97%) of 100 patients (median, 3 ﬁndings per
patient; range, 1-9 ﬁndings). The most common ﬁndings are
summarized in Table 2.
A total of 197 (56.6%) of 348 ﬁndings were classiﬁed as category
I (benign/not clinically signiﬁcant), 113 (32.5%) of 348 ﬁndings
were classiﬁed as category IIA (benign and potentially clinically
signiﬁcant), and 38 (10.9%) of 348 ﬁndings were classiﬁed as
category IIB (indeterminate and potentially malignant). There were
no category III (clinically urgent) ﬁndings.
The category IIB (indeterminate) ﬁndings are summarized in
Table 3 and were located at the following sites: liver (n ¼ 7), spleen
(n ¼ 2), adrenal (n ¼ 5), prostate (n ¼ 5), lymph nodes (n ¼ 5),
and others (n ¼ 14). Thirty-four patients had one indeterminate
ﬁnding; 2 patients had 2 indeterminate ﬁndings; 2 patients had 3
and 4 indeterminate ﬁndings respectively.
Each additional sequence (T1-W, CE T1-W, or DWI) resulted
in increased diagnostic conﬁdence for lesion characterization
compared to the initial T2-weighted imaging (Figure 1). T1-
weighted Dixon sequences increased diagnostic conﬁdence in the
characterization of 12 (31.6%) of 38 ﬁndings because of its ability
to demonstrate microscopic fat and hemorrhage; 5 indeterminate
adrenal lesions were conﬁrmed as adrenal adenomas with the T1-W
Dixon sequences. CE T1-W sequences, only possible in 82 (82%)
of 100 patients because of renal impairment in the remaining pa-
tients, increased diagnostic conﬁdence in characterization of 16
(50%) of 32 ﬁndings compared to T2-W imaging alone and was
particularly helpful for hepatic and renal lesions. DWI sequences
increased diagnostic conﬁdence in characterization of 21 (55.3%) of
38 ﬁndings compared to T2-W imaging alone. T1-weighted Dixon,
DWI, and CE T1-W sequences did not improve characterization of
2 subcentimeter pulmonary nodules.
In 16 (42.1%) of 38 patients, further investigation of indetermi-
nate ﬁndings was recommended (further imaging ¼ 5, histology ¼
11). Eight (50%) of 16 patients were investigated further. For the
remaining 8 ﬁndings, one patient died before further investigation
could be undertaken. The cause of death was progressive myeloma,
and the hepatosplenic lesions likely represented extramedullarydisease sites. Of the 7 ﬁndings not investigated initially, 5 of 7 ﬁndings
scored as low clinical signiﬁcance. Two of 7 ﬁndings were scored as
moderate by clinical consensus, for whom further investigations were
recommended; transvaginal ultrasound in patient 5, found to have
incidental endometrial thickening, and serum prostate-speciﬁc anti-
gen with or without histology in patient 7 with possible incidental
prostatic lesion (Table 4).
No additional new malignancies were detected in this cohort.
There were 3 cases of known concurrent malignancy (2 prostate
cancer and 1 parotid Warthin tumor). There were also 2 cases of
extramedullary plasmacytoma within lymph nodes. After exclusion of
the 3 cases of known malignancy, 19 (54.3%) of 35 indeterminate
ﬁndings could be fully characterized via T1-Dixon, DWI, and/or CE
T1-W sequences such that no further investigations were required.
Discussion
Incidental ﬁndings are relatively common in patients with
plasma-cell disorders undergoing WBMRI and were present in 97%
of patients in our cohort. The majority could be characterized fullyClinical Lymphoma, Myeloma & Leukemia Month 2018 - 3
Table 3 Indeterminate Findings by Various Imaging Modalities, Risk of Malignancy Scores, and Final Diagnoses
Indeterminate Finding (Malignancy
Likelihood on T2-W Images) T1-W CE T1-W DWI
Further
Management
Advised
Further
Management
Performed inal Diagnosis or Management Recommended
Adrenal lesion (3) II (1) I (3) I (3) N NA Adrenal adenoma
Adrenal lesion (3) II (1) I (3) I (3) N NA Adrenal adenoma
Adrenal lesion (3) II (1) I (3) I (3) N NA Adrenal adenoma
Adrenal lesion (3) II (1) I (3) I (3) N NA Adrenal adenoma
Adrenal enlargement (3) II (1) I (3) I (3) N NA Adenomatous hyperplasia
Adnexal lesion (2) I (2) II (3) II (3) Y N Dedi ted pelvic imaging recommended; interval WBMRI demonstrated
reduction in size
Endometrial thickening (3) II (1) I (3) II (1) N NA Intracavitary hemorrhage
Endometrial thickening (3) I (3) II (3) II (3) Y N No further investigation performed
Liver lesion (2) I (2) I (2) II (1) N NA Benign cyst
Liver lesion (3) I (3) — II (2) Y Y Hemangioma (dedicated hepatic MRI)
Liver lesion (3) I (3) II (1) I (3) N NA Hemangioma
Liver lesion (4) I (4) II (5) II (5) Y Y Hemangioma (liver biopsy)
Liver lesion (4) I (4) II (4) II (4) Y N atient died before further investigation could be performed
Subcentimeter liver lesion (3) I (3) I (3) I (3) Y N D icated hepatic MRI suggested; no further imaging performed
Right upper lobe lung lesion, ipsilateral,
mediastinal, and hilar node (3)
I (3) — II (4) Y Y T berculosis with resolution of imaging ﬁndings after treatment
Subcentimeter lung lesion (2) I (2) I (2) I (2) Y N Stable on follow-up imaging
Subcentimeter lung lesion (3) I (3) — I (3) Y N Fo w-up CT chest recommended as per British Thoracic Society
guidelines; no further imaging performed
Parotid lesion (3) II (3) II (4) I (3) N NA Warthin tumor
Pancreatic lesion (2) I (2) II (1) II (1) N NA Benign pancreatic cyst
Pancreatic lesion (2) I (2) II (1) II (1) N NA Benign pancreatic cyst
Prostate lesion (3) I (3) I (3) II (4) N NA Prostate cancer (previously diagnosed)
Prostate lesion (3) I (3) — II (4) N NA Prostate cancer (previously diagnosed)
Prostate lesions (3) I (3) I (3) II (4) Y Y Normal serum PSA; no further investigation
Prostate lesion (2) I (2) I (2) II (3) Y N Correlation with serum PSA level with or without histology
recommended; no further investigation
Prostate lesion (3) I (3) I (3) I (3) Y Y Reviewed by urology
Renal lesion (4) I (4) II (5) I (4) Y Y Oncocytoma (surgery)
Renal lesion (3) II (1) II (1) I (3) N NA Hemorrhagic renal cyst
Renal lesion (2) II (1) — I (2) N NA Hemorrhagic renal cyst
Splenic lesion (4) I (4) II (4) II (4) N NA atient died before further investigation could be performed
Perinephric thickening (2) II (1) — I (2) N NA Perinephric hematoma
Retroperitoneal cystic lesion (3) I (3) II (2) II (2) N NA Benign nerve sheath tumor
Supraclavicular nodes (3) I (3) II (4) II (4) Y Y Plasmacytoma
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Olwen Westerland et alwith a comprehensive protocol such that no further investigations
were required. Over half of the detected incidental ﬁndings were
classiﬁed as not clinically signiﬁcant or common in asymptomatic
subjects. No new malignancies were detected in our cohort,
although there were preexisting malignancies and extraosseous sites
of disease.
T1-W Dixon sequences were helpful in the characterization of
lesions containing microscopic fat (eg, adrenal adenoma) and
macroscopic fat (eg, lipoma), as well as in the detection of hemor-
rhage (eg, hemorrhagic material within the uterine cavity and
hemorrhagic renal cysts). CE T1-W sequences were particularly
helpful in the characterization of hepatic and renal lesions. DWI
sequences assisted in the characterization of prostatic lesions, hepatic
lesions, and lymph nodes.
Our study reports a higher percentage of incidental ﬁndings than
previously published WBMRI studies of various populations, where
incidental ﬁndings have been found in up to 80% of patients.5 In
the general population-based Study of Health in Pomerania (SHIP),
incidental ﬁndings were detected in 36.2% of participants
(n ¼ 2500), 5.9% of which were malignant.4 In the SHIP study,
incidental ﬁndings were categorized as I (normal/common in
asymptomatic subjects), II (requiring further medical evaluation), or
III (requiring immediate referral). In another study, incidental
ﬁndings were detected in 42% of neuroﬁbromatosis patients
(n ¼ 247),6 whereas among a cohort of lymphoma patients
(n ¼ 119), 79.8% had one or more incidental ﬁnding, although
only 6% were classiﬁed as clinically signiﬁcant.5
There is only one other study to date evaluating incidental
ﬁndings in WBMRI in myeloma, in which incidental ﬁndings were
detected in 38% of patients.7 In this retrospective study, the authors
reviewed WBMRI (comprising axial DWI sequences with corre-
sponding apparent diffusion coefﬁcient maps and T1-W and T2-W
sagittal whole spine sequences) in 110 patients. Seventy incidental
ﬁndings were documented, of which 14 (20%) were equivocal or
indeterminate. Clinical correlation and review of previous imaging
was recommended as the initial action in 57% (8/14 patients) with
indeterminate incidental ﬁndings, and only 3% required further
characterization as the initial action.
The comparatively higher incidental ﬁnding detection rate in our
cohort compared to this study partly reﬂects the differences in
imaging protocol. The WBMRI protocol used in the study by Wale
et al7 only included axial DWI sequences, whereas we used a more
comprehensive protocol of T2-W, T1-W, CE T1-W, and DWI
sequences. Greater standardization of WBMRI protocols could
reduce such variances. The greater proportion of incidental ﬁndings
requiring further investigation in our cohort may also be partially
attributed to variations in individual radiologist threshold for
reporting some incidental ﬁndings and also intrinsic differences in
the incidental ﬁndings encountered. For example, no prostatic
lesions were reported in the study by Wale et al.
There are no studies to date that have speciﬁcally addressed the
value of individual sequences in characterizing incidental ﬁndings.
The value of DWI sequences in the baseline assessment of focal and
diffuse marrow inﬁltration is clear,8 and there is growing evidence
for its use in myeloma response assessment.9 Contrast-enhanced
sequences are not used in all WBMRI protocols, particularly
given the prevalence of renal impairment in this population;Clinical Lymphoma, Myeloma & Leukemia Month 2018 - 5
Figure 1 Various Imaging Results of Patient With Myeloma. (A) Whole Body MRI 1.5 T Selected Axial T2 HASTE. (B) T1-Dixon Water
Only. (C) DWI (B900). (D) ADC. Imaging Revealed Incidental Complex, Cystic Left Renal Mass (Solid White Arrow). Patient
Underwent Nephrectomy With Histologic Diagnosis of Oncocytoma. Also Evident Is Focal Vertebral Body Myeloma Lessons
(C, Broken Arrow)
Abbreviations: ADC ¼ apparent diffusion coefﬁcient; DWI ¼ diffusion weighted; HASTE ¼ half-Fourier acquisition single-shot turbo spin echo; MRI ¼ magnetic resonance imaging.
Incidental Findings on WBMRI
6 - Clihowever, studies have shown that they improve sensitivity for
detection of bone lesions,10 and hence the inclusion of postcontrast
imaging in our WBMRI protocol. This study demonstrates that
both DWI and CE T1-W imaging increased diagnostic conﬁdence
in characterization of incidental ﬁndings.
Nevertheless, there are limitations to this study. Incidental
ﬁndings were recorded regardless of clinical importance, so our
detection rate is likely to exceed that of a typical clinical report.
Second, because our study was retrospective in nature, it was not
possible to determine if further investigation of indeterminate
ﬁndings had resulted in action in all patients, even after elec-
tronic patient record review. However, of the 7 cases identiﬁed,Table 4 Clinical Consensus of Signiﬁcance of Indeterminate Findin
Patient No. Indeterminate Finding Further Investig
1 5 mm subpleural lung lesion CT chest follow-up as
Society g
2 7 mm liver lesion Dedicated h
3 10 mm subpleural lung lesion CT chest follow-up as
Society g
4 Endometrial thickening Clinical correlation with
5 Adnexal lesion Correlation with previous
6 Prostate lesion Correlation with PSA w
7 SCF and cervical nodes Clinical correlation w
sugge
Abbreviations: CT ¼ computed tomography; FNA ¼ ﬁne needle aspiration; MRI ¼ magnetic resonan
aLow or moderate indicates meriting further routine investigation; high, meriting urgent investigation
nical Lymphoma, Myeloma & Leukemia Month 2018only 2 were considered to be of moderate clinical signiﬁcance by
clinical consensus. Additionally, only one reader performed the
imaging analysis, so intra- and interobserver variation could not
be assessed. It is also theoretically possible that additional inci-
dental ﬁndings could be demonstrated on supplementary se-
quences such as CE T1-W sequences (eg, hypervascular
hepatosplenic lesions); however, this potential issue was not
encountered in our study cohort. Finally, the grading score used
to assess malignancy likelihood of indeterminate ﬁndings has not
been validated for use in previous studies. This study could be
further improved by incorporating a second reader and using a
prospective approach.gs
ation Advised Investigated Clinical Signiﬁcancea
per British Thoracic
uidelines
N Low
epatic MRI N Low
per British Thoracic
uidelines
N Low
or without pelvic US N Moderate
imaging and pelvic US N Low
ith or without histology N Moderate
ith or without FNA
sted
N Low
ce imaging; PSA ¼ prostate-speciﬁc antigen; SCF ¼ supraclavicular fossa; US ¼ ultrasound.
.
Olwen Westerland et alConclusion
Incidental ﬁndings are relatively common in patients with
plasma-cell disorders undergoing WBMRI. The majority of ﬁndings
are benign in nature and can be characterized fully with a
comprehensive protocol, necessitating few additional investigations.
Our ﬁndings should provide reassurance to clinicians requesting
WBMRI.
Clinical Practice Points
 There has only been one previous study assessing the frequency
and signiﬁcance of incidental ﬁndings at WBMRI in myeloma,
in which incidental ﬁndings were detected in 38% of patients. In
our study, the detection rate was signiﬁcantly higher (97%). This
difference may be explained by differences in imaging protocol
and by variations in individual radiologist thresholds for
reporting some incidental ﬁndings.
 The results of this study demonstrate that although incidental
ﬁndings are common at WBMRI, most are not clinically sig-
niﬁcant. The inclusion of contrast-enhanced and DWI sequences
in WBMRI protocols substantially improves reader conﬁdence in
characterization of incidental ﬁndings, thus reducing the need for
further additional investigations (potentially resulting in patient
anxiety and additional health care costs).
 Our results should provide reassurance to clinicians requesting
WBMRI with regard to possible incidental ﬁndings, and should
provide further evidence to support the inclusion of contrast-
enhanced and DWI sequences in WBMRI protocols additional
to their value in detection of bone disease in myeloma.Acknowledgments
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